Infections

All Conditions

Symptoms and General Pathology

Neoplasms

Digestive System Diseases

Rare Diseases

Communicable Diseases

Stomach Neoplasms

Helicobacter Infections

Precancerous Conditions

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Bacterial Infections

Gram-Negative Bacterial Infections

Mycoses

Bacterial Infections and Mycoses

Stomach Cancer

Anti-Infective Agents

All Drugs and Chemicals

Gastrointestinal Agents

Amoxicillin

Clarithromycin

Omeprazole

Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.

OAC triple therapy

Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.

Placebo

Jie J Wang, M.D.

Xi Wang, M.D.

Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. Although gastric cancer has a multifactorial etiology, infection with H. pylori is highly associated with gastric carcinogenesis. Therefore, eradication of H. pylori infection appears to reduce the risk of gastric cancer. However, several recent controlled interventional trials by H. pylori eradication to prevent gastric cancer have yielded disappointing results. The exact effect of H.pylori eradication on prevention of gastric cancer is unclear up to now. To clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether H pylori eradication would reduce the incidence of gastric cancer in a high-risk population in China.

Helicobacter Pylori Eradication to Prevent Gastric Cancer

Helicobacter Pylori Eradication to Prevent Gastric Cancer in a High-Risk Population of China: A Randomized Controlled Trial

The incidence of gastric cancer in the two groups

The histopathological changes of atrophic gastritis or intestinal metaplasia in the two groups

Jie-Jun Wang

Atrophy

Gastritis, Atrophic

Gastritis

Rabeprazole

Pantoprazole

Lansoprazole

Dexlansoprazole

Proton Pump Inhibitors

Antacids

Anti-Ulcer Agents

Enzyme Inhibitors

Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).

1. Pre ESD (endoscopic submucosal dissection)

   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
   * Use of PPI for 2 months
2. Post ESD 1 (After 2 months)

   * Assess the distribution of helicobacter pylori after using PPI.
   * Stop of PPI
3. Post ESD 2 (After 4 months)

   * Assess the distribution of helicobacter pylori after stop of PPI.

PPI (proton pump inhibitor)

Ji Yong Ahn, Professor

The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.

Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during, and after using PPI.

Helicobacter Pylori and Proton Pump Inhibitor

Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor

Asan Medical Center

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Helicobacter Pylori Eradication to Prevent Gastric Cancer	NCT01133951	Helicobacter In... Stomach Neoplas...	OAC triple ther... Placebo	30 Years - 59 Years	Second Military Medical University
Helicobacter Pylori and Proton Pump Inhibitor	NCT02449941	Helicobacter In...	PPI (proton pum...	19 Years - 65 Years	Asan Medical Center

Spots Global Cancer Trial Database for helicobacter infections